Intravitreal Bevacizumab for Diabetic Macular Edema
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00703235|
Recruitment Status : Unknown
Verified June 2008 by Isfahan Ophthalmology Research Center.
Recruitment status was: Enrolling by invitation
First Posted : June 23, 2008
Last Update Posted : June 23, 2008
Diabetic macular edema is a common cause of visual loss among diabetic patients. Studies have demonstrated the role of vascular endothelial growth factor (VEGF) in the pathogenesis of edema.
This study designed to evaluate the effect of Intravitreal injection of a recombinant monoclonal anti-VEGF antibody, Bevacizumab, for treatment of diabetic macular edema.
|Condition or disease||Intervention/treatment||Phase|
|Macular Edema Diabetic Retinopathy||Drug: Bevacizumab||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|